Viva Pharma, UAB - financials and debts

Company age: 20 y. 7 mo.

Update

Viva Pharma - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 196 355 - - - 4,095 18,810 20,507
Profit before tax - - - - - - - -
Net profit -6,414 -569 -1,311 -9,046 8,788 735 10,211 8,312
Equity -82,876 -83,443 -84,755 -93,800 -84,991 -84,255 -74,044 -65,732
Liabilities 120,666 121,538 119,253 128,553 91,340 117,158 105,195 93,951
Non-current assets 574 291 14 448 1,052 555 203 30
Current assets 37,188 37,798 34,440 34,292 32,711 32,341 30,924 28,189
Total assets 37,762 38,089 34,454 34,740 33,763 32,896 31,127 28,219
Taxes paid
STI taxes - - - - - - 1 9
Financial indicators
Revenue change y/y -99.3% +81.1% - - - - +359.3% +9.0%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. -17.0% -1.5% -3.8% -26.0% 26.0% 2.2% 32.8% 29.5%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. - - - - - - - -
Profit margin Net profit margin. Shows the overall profitability of the company. -3272.4% -160.3% - - - 17.9% 54.3% 40.5%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. - - - - - - - -
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - - - - - - - -
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 196 - - - - 4,095 18,810 20,507

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Viva Pharma - Social security debts

From To Debt, €
2026-07-23 2026-07-23 33.27
2026-07-19 2026-07-22 33.02
2026-07-16 2026-07-17 33.02
2026-06-16 2026-06-21 33.83
2026-05-18 2026-05-24 34.64
2026-04-24 2026-04-26 35.45
2026-04-20 2026-04-23 35.24
2026-03-29 2026-04-15 0.05
2026-03-27 2026-03-27 36.05
2026-03-25 2026-03-26 0.05
2026-03-17 2026-03-24 36.05
2026-03-15 2026-03-16 0.86
2026-02-22 2026-03-11 0.86
2026-02-18 2026-02-21 36.05
2026-01-23 2026-02-17 0.86
2026-01-22 2026-01-22 30.86
2026-01-16 2026-01-21 30.65
2025-12-30 2025-12-30 3.18
2025-12-28 2025-12-29 3.75
2025-12-16 2025-12-27 33.75
2025-11-19 2025-12-15 2.20
2025-11-18 2025-11-18 32.20
2025-10-23 2025-11-17 0.65
2025-10-20 2025-10-22 0.61
2025-10-16 2025-10-19 30.61
2025-09-16 2025-09-24 6.22
2025-08-28 2025-08-29 4.67
2025-08-19 2025-08-24 4.67
2025-07-16 2025-07-28 2.12
2024-06-18 2024-06-24 0.75
2024-05-16 2024-05-27 1.60
2024-04-23 2024-04-25 2.45
2024-04-16 2024-04-22 2.44
2024-03-18 2024-03-25 3.29
2024-02-19 2024-02-21 1.14
2023-09-18 2023-09-24 3.38
2023-08-17 2023-08-24 3.38
2023-07-24 2023-07-24 3.38
2023-07-18 2023-07-23 3.35
2023-06-16 2023-06-21 3.35
2023-05-16 2023-05-23 3.35
2023-04-18 2023-04-23 3.33
2023-03-16 2023-03-23 3.33
2023-02-17 2023-02-20 3.33
2022-09-16 2022-09-22 0.48
2022-08-23 2022-08-24 0.33
2022-07-18 2022-07-24 0.15
2022-06-16 2022-06-26 3.15
2022-05-17 2022-05-29 3.00
2022-04-28 2022-04-28 2.85
2022-04-19 2022-04-27 2.79
2022-03-16 2022-03-20 2.79
2022-02-17 2022-02-27 2.79
2022-01-25 2022-01-26 1.33
2022-01-18 2022-01-24 20.83
2021-12-20 2022-01-17 1.35
2021-12-16 2021-12-19 21.35
2021-11-29 2021-12-15 1.87
2021-11-16 2021-11-25 19.48
2021-10-18 2021-10-25 19.48
2021-09-16 2021-09-26 19.48

Viva Pharma - VMI tax arrears

As of 2026-09-02, the amount of overdue STI tax debt of the company Viva Pharma is: 2 €

From To Overdue, €
2026-07-02 2026-09-02 2.0
2025-05-28 2025-06-02 9.0

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.